Brainstorm Cell Therapeutics Inc. (BCLI) 10-Year Financial Performance & Capital Metrics

BCLI • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersAlzheimer's & Neurodegenerative

AboutBrainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; and Phase II clinical trial for the treatment of progressive multiple sclerosis and alzheimer's disease, as well as for other neurodegenerative diseases. The company has a partnership with Catalent for manufacturing NurOwn. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.Show more

Revenue $849K
EBITDA -$11M +45.9%
Net Income $12M +167.6%
EPS (Diluted) 2.19 +148.9%
Gross Margin 100%
EBITDA Margin -1349%
Operating Margin -1377.27%
Net Margin 1369.02%
ROE -
ROIC -
Debt/Equity -
Interest Coverage -151.86

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Healthy 5Y average net margin of 1369.0%

✗Weaknesses

✗Negative free cash flow
✗Weak momentum: RS Rating 10 (bottom 10%)
✗Shares diluted 38.3% in last year
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM147.52%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM10.18%

EPS CAGR

10Y-

5Y-

3Y-

TTM46.63%

ROCE

10Y Avg-137.44%

5Y Avg-172.23%

3Y Avg-219.56%

Latest-

Peer Comparison

Alzheimer's & Neurodegenerative

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
ANVSAnnovis Bio, Inc.	84.81M	3.20	-0.00			-189.15%
CLNNClene Inc.	60.19M	5.11	-0.90	-47.71%	-142.5%	-17.38%
ABOSAcumen Pharmaceuticals, Inc.	112.67M	1.86	-1.09			-143.12%	0.16
BHVNBiohaven Ltd.	1.58B	11.92	-1.28			-198.83%	0.09
IKTInhibikase Therapeutics, Inc.	200.09M	1.65	-1.42	-100%		-65.37%	0.00
ALECAlector, Inc.	198.66M	1.82	-1.48	3.6%	-156.03%	-186.68%	0.34
CGTXCognition Therapeutics, Inc.	121.82M	1.38	-1.62			-76.61%	0.04
ATHEAlterity Therapeutics Limited	60M	3.31	-2.90	35.32%	-330.63%	-73.75%	0.00

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	-366K	0	0	0	0	849K
Revenue Growth %	-	-	-	-	-	1%	-	-	-	-
Cost of Goods Sold+	87K	77K	85K	110K	366K	219K	260K	285K	265K	240K
COGS % of Revenue	-	-	-	-	-1%	-	-	-	-	0.28%
Gross Profit+	-87K	-77K	-85K	-110K	-732K	-219K	-260K	-285K	-265K	849K
Gross Margin %	-	-	-	-	2%	-	-	-	-	1%
Gross Profit Growth %	-	0.11%	-0.1%	-0.29%	-5.65%	0.7%	-0.19%	-0.1%	0.07%	4.2%
Operating Expenses+	8.54M	5.08M	5M	14.06M	23M	31.68M	24.54M	24.82M	21.17M	11.45M
OpEx % of Revenue	-	-	-	-	-62.84%	-	-	-	-	13.49%
Selling, General & Admin	3.59M	2.83M	4.02M	5.77M	5.8M	9.36M	9.3M	10.87M	10.69M	7.04M
SG&A % of Revenue	-	-	-	-	-15.84%	-	-	-	-	8.29%
Research & Development	4.95M	2.25M	977K	8.29M	17.2M	22.33M	15.23M	13.96M	10.48M	4.41M
R&D % of Revenue	-	-	-	-	-47.01%	-	-	-	-	5.2%
Other Operating Expenses	0	0	0	0	0	0	0	0	0	0
Operating Income+	-8.54M	-5.08M	-5M	-14.06M	-23M	-31.68M	-24.54M	-24.82M	-21.44M	-11.69M
Operating Margin %	-	-	-	-	62.84%	-	-	-	-	-13.77%
Operating Income Growth %	-0.15%	0.4%	0.02%	-1.81%	-0.64%	-0.38%	0.23%	-0.01%	0.14%	0.45%
EBITDA+	-8.45M	-5.01M	-4.91M	-13.95M	-22.84M	-31.46M	-24.28M	-24.54M	-21.17M	-11.45M
EBITDA Margin %	-	-	-	-	62.4%	-	-	-	-	-13.49%
EBITDA Growth %	-0.16%	0.41%	0.02%	-1.84%	-0.64%	-0.38%	0.23%	-0.01%	0.14%	0.46%
D&A (Non-Cash Add-back)	87K	77K	85K	110K	164K	219K	260K	285K	265K	240K
EBIT	-8.49M	-4.98M	-4.95M	-13.95M	-23.25M	-31.81M	-24.46M	-24.28M	-17.19M	-11.55M
Net Interest Income+	48K	101K	47K	0	252	-127K	82K	545K	0	-77K
Interest Income	48K	101K	47K	0	252	127	82K	545K	0	0
Interest Expense	0	0	0	0	0	0	0	0	0	77K
Other Income/Expense	48K	101K	47K	115K	-252K	-127K	82K	545K	4.25M	70K
Pretax Income+	-8.49M	-4.98M	-4.95M	-13.95M	-23.25M	-31.81M	-24.46M	-24.28M	-17.19M	11.62M
Pretax Margin %	-	-	-	-	63.53%	-	-	-	-	13.69%
Income Tax+	0	0	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-8.49M	-4.98M	-4.95M	-13.95M	-23.25M	-31.81M	-24.46M	-24.28M	-17.19M	11.62M
Net Margin %	-	-	-	-	63.53%	-	-	-	-	13.69%
Net Income Growth %	0.08%	0.41%	0.01%	-1.82%	-0.67%	-0.37%	0.23%	0.01%	0.29%	1.68%
Net Income (Continuing)	-8.49M	-4.98M	-4.95M	-13.95M	-23.25M	-31.81M	-24.46M	-24.28M	-17.19M	11.62M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-6.88	-4.00	-3.92	-10.05	-13.64	-14.09	-10.09	-9.93	-4.48	2.19
EPS Growth %	0.17%	0.42%	0.02%	-1.56%	-0.36%	-0.03%	0.28%	0.02%	0.55%	1.49%
EPS (Basic)	-6.88	-4.00	-3.92	-10.05	-13.64	-14.09	-10.09	-9.93	-4.48	2.19
Diluted Shares Outstanding	1.23M	1.25M	1.26M	1.39M	1.71M	2.26M	2.42M	2.45M	3.84M	5.31M
Basic Shares Outstanding	1.23M	1.25M	1.26M	1.39M	1.7M	2.26M	2.42M	2.45M	3.84M	5.31M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	16.79M	10.44M	9.62M	10.27M	3.36M	43.24M	23.28M	3.11M	1.9M	385K
Cash & Short-Term Investments	15.96M	9.99M	7.76M	7.06M	569K	41.94M	22.09M	2.98M	1.3M	187K
Cash Only	428K	547K	2.48M	942K	536K	37.83M	18.86M	772K	1.3M	187K
Short-Term Investments	15.53M	9.44M	5.27M	6.12M	33K	4.11M	3.24M	2.21M	0	0
Accounts Receivable	759K	306K	672K	2.01M	0	0	0	91K	51K	63K
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	27.08
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	0	2.63M	304K	86K	0	23K	135K
Total Non-Current Assets+	292K	322K	1.8M	958K	3.17M	8.02M	6M	5.34M	2.31M	1.45M
Property, Plant & Equipment	271K	297K	392K	651K	3.13M	7.96M	5.95M	5.32M	2.1M	1.24M
Fixed Asset Turnover	-	-	-	-	-0.12x	-	-	-	-	0.68x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	20	16	13	16	13K	27K	17K	9	3K	0
Long-Term Investments	0	0	0	0	0	0	0	0	185K	184K
Other Non-Current Assets	20.98K	24.98K	1.41M	306.98K	32K	26K	27K	22.99K	19K	22K
Total Assets+	17.08M	10.77M	11.42M	11.23M	6.53M	51.26M	29.28M	8.45M	4.21M	1.83M
Asset Turnover	-	-	-	-	-0.06x	-	-	-	-	0.46x
Asset Growth %	0.72%	-0.37%	0.06%	-0.02%	-0.42%	6.84%	-0.43%	-0.71%	-0.5%	-0.56%
Total Current Liabilities+	2.95M	864K	5.54M	6.21M	17.65M	11.23M	6.32M	8.8M	7.8M	8.98M
Accounts Payable	1.45M	712K	2.1M	4.55M	14.68M	5.42M	3.7M	6.22M	4.95M	6.08M
Days Payables Outstanding	6.09K	3.38K	9.02K	15.09K	14.64K	9.03K	5.19K	7.97K	6.82K	9.25K
Short-Term Debt	0	0	0	0	0	0	0	0	603K	0
Deferred Revenue (Current)	0	0	1000K	0	0	0	0	0	0	0
Other Current Liabilities	0	0	0	622K	714K	1.9M	1.07M	1.06M	2.24M	2.35M
Current Ratio	5.69x	12.09x	1.74x	1.65x	0.19x	3.85x	3.69x	0.35x	0.24x	0.04x
Quick Ratio	5.69x	12.09x	1.74x	1.65x	0.19x	3.85x	3.69x	0.35x	0.24x	0.04x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	0	0	0	1.1M	4.56M	3.62M	2.67M	1.27M	618K
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	1.1M	4.56M	3.62M	2.67M	672K	171K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	0	0	594K	447K
Total Liabilities	2.95M	864K	5.54M	6.21M	18.76M	15.79M	9.94M	11.47M	9.07M	9.6M
Total Debt+	0	0	0	0	2.37M	7.22M	5.08M	4.09M	1.27M	720K
Net Debt	-428K	-547K	-2.48M	-942K	1.83M	-30.61M	-13.78M	3.32M	-25K	533K
Debt / Equity	-	-	-	-	-	0.20x	0.26x	-	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-	-	-	-	-151.86x
Total Equity+	14.13M	9.9M	5.88M	5.02M	-12.22M	35.46M	19.34M	-3.02M	-4.86M	-7.76M
Equity Growth %	1.12%	-0.3%	-0.41%	-0.15%	-3.44%	3.9%	-0.45%	-1.16%	-0.61%	-0.6%
Book Value per Share	11.45	7.95	4.65	3.61	-7.17	15.71	7.98	-1.23	-1.27	-1.46
Total Shareholders' Equity	14.13M	9.9M	5.88M	5.02M	-12.22M	35.46M	19.34M	-3.02M	-4.86M	-7.76M
Common Stock	11K	11K	11K	11K	11K	12K	12K	12K	13K	14K
Retained Earnings	-70.14M	-75.12M	-80.08M	-94.02M	-117.28M	-149.09M	-173.54M	-197.82M	-215.01M	-226.64M
Treasury Stock	0	0	0	0	0	-116K	-116K	-116K	-116K	-116K
Accumulated OCI	0	0	0	4.41M	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-7.41M	-5.86M	-2.36M	-12.39M	-11.25M	-35.19M	-26.27M	-19.32M	-20.46M	-9.09M
Operating CF Margin %	-	-	-	-	30.73%	-	-	-	-	-10.71%
Operating CF Growth %	-0.65%	0.21%	0.6%	-4.24%	0.09%	-2.13%	0.25%	0.26%	-0.06%	0.56%
Net Income	-8.49M	-4.98M	-4.95M	-13.95M	-23.25M	-31.81M	-24.46M	-24.28M	-17.19M	-11.62M
Depreciation & Amortization	87K	77K	85K	110K	164K	219K	260K	285K	265K	240K
Stock-Based Compensation	835K	635K	554K	917K	789K	2.56M	1.37M	1.68M	1.49M	750K
Deferred Taxes	0	0	0	0	0	0	0	1.34M	0	0
Other Non-Cash Items	108K	121K	62K	102K	0	0	0	-1.34M	-4.53M	-147K
Working Capital Changes	50K	-1.71M	1.89M	431K	11.05M	-6.16M	-3.43M	2.99M	-496K	1.69M
Change in Receivables	204K	379K	-2.79M	-238K	690K	1.49M	335K	1.07M	-475K	401K
Change in Inventory	0	0	975K	0	0	0	0	0	0	0
Change in Payables	-373K	-824K	1.08M	3.12M	10.13M	-9.26M	-1.72M	2.52M	-1.27M	1.13M
Cash from Investing+	-11.28M	5.98M	3.99M	-1.22M	5.62M	-4.45M	323K	998K	2.19M	12K
Capital Expenditures	-45K	-103K	-180K	-369K	-473K	-378K	-330K	-29K	-18K	0
CapEx % of Revenue	-	-	-	-	-1.29%	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-11.24M	6.08M	4.17M	-849K	6.09M	-4.07M	653K	0	2.21M	12K
Cash from Financing+	14.87M	0	314K	12.06M	5.22M	76.94M	6.97M	238K	18.98M	7.97M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	14.87M	0	314K	12.06M	3.16M	16.32M	5K	0	0	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-7.45M	-5.96M	-2.54M	-12.76M	-11.72M	-35.57M	-26.59M	-19.35M	-20.48M	-9.09M
FCF Margin %	-	-	-	-	32.02%	-	-	-	-	-10.71%
FCF Growth %	-0.6%	0.2%	0.57%	-4.01%	0.08%	-2.04%	0.25%	0.27%	-0.06%	0.56%
FCF per Share	-6.04	-4.78	-2.01	-9.19	-6.87	-15.76	-10.97	-7.91	-5.33	-1.71
FCF Conversion (FCF/Net Income)	0.87x	1.18x	0.48x	0.89x	0.48x	1.11x	1.07x	0.80x	1.19x	-0.78x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-81.6%	-41.46%	-62.76%	-256.02%	-	-273.75%	-89.25%	-297.38%	-	-
Return on Invested Capital (ROIC)	-79.41%	-33.07%	-58.8%	-282.35%	-	-	-353.35%	-634.18%	-	-
Gross Margin	-	-	-	-	200%	-	-	-	-	100%
Net Margin	-	-	-	-	6353.28%	-	-	-	-	1369.02%
Debt / Equity	-	-	-	-	-	0.20x	0.26x	-	-	-
Interest Coverage	-	-	-	-	-	-	-	-	-	-151.86x
FCF Conversion	0.87x	1.18x	0.48x	0.89x	0.48x	1.11x	1.07x	0.80x	1.19x	-0.78x
Revenue Growth	-	-	-	-	-	100%	-	-	-	-

Frequently Asked Questions

Valuation & Price

Brainstorm Cell Therapeutics Inc. (BCLI) has a price-to-earnings (P/E) ratio of 0.3x. This may indicate the stock is undervalued or faces growth challenges.

Growth & Financials

Brainstorm Cell Therapeutics Inc. (BCLI) reported $0.8M in revenue for fiscal year 2024.

Brainstorm Cell Therapeutics Inc. (BCLI) grew revenue by 0.0% over the past year. Growth has been modest.

Brainstorm Cell Therapeutics Inc. (BCLI) reported a net loss of $11.4M for fiscal year 2024.

Dividend & Returns

Brainstorm Cell Therapeutics Inc. (BCLI) had negative free cash flow of $9.5M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Brainstorm Cell Therapeutics Inc. (BCLI) 10-Year Financial Performance & Capital Metrics

BCLI • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersAlzheimer's & Neurodegenerative

Revenue $849K
EBITDA -$11M +45.9%
Net Income $12M +167.6%
EPS (Diluted) 2.19 +148.9%
Gross Margin 100%
EBITDA Margin -1349%
Operating Margin -1377.27%
Net Margin 1369.02%
ROE -
ROIC -
Debt/Equity -
Interest Coverage -151.86

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Healthy 5Y average net margin of 1369.0%

✗Weaknesses

✗Negative free cash flow
✗Weak momentum: RS Rating 10 (bottom 10%)
✗Shares diluted 38.3% in last year
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM147.52%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM10.18%

EPS CAGR

10Y-

5Y-

3Y-

TTM46.63%

ROCE

10Y Avg-137.44%

5Y Avg-172.23%

3Y Avg-219.56%

Latest-

Peer Comparison

Alzheimer's & Neurodegenerative

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
ANVSAnnovis Bio, Inc.	84.81M	3.20	-0.00			-189.15%
CLNNClene Inc.	60.19M	5.11	-0.90	-47.71%	-142.5%	-17.38%
ABOSAcumen Pharmaceuticals, Inc.	112.67M	1.86	-1.09			-143.12%	0.16
BHVNBiohaven Ltd.	1.58B	11.92	-1.28			-198.83%	0.09
IKTInhibikase Therapeutics, Inc.	200.09M	1.65	-1.42	-100%		-65.37%	0.00
ALECAlector, Inc.	198.66M	1.82	-1.48	3.6%	-156.03%	-186.68%	0.34
CGTXCognition Therapeutics, Inc.	121.82M	1.38	-1.62			-76.61%	0.04
ATHEAlterity Therapeutics Limited	60M	3.31	-2.90	35.32%	-330.63%	-73.75%	0.00

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	-366K	0	0	0	0	849K
Revenue Growth %	-	-	-	-	-	1%	-	-	-	-
Cost of Goods Sold+	87K	77K	85K	110K	366K	219K	260K	285K	265K	240K
COGS % of Revenue	-	-	-	-	-1%	-	-	-	-	0.28%
Gross Profit+	-87K	-77K	-85K	-110K	-732K	-219K	-260K	-285K	-265K	849K
Gross Margin %	-	-	-	-	2%	-	-	-	-	1%
Gross Profit Growth %	-	0.11%	-0.1%	-0.29%	-5.65%	0.7%	-0.19%	-0.1%	0.07%	4.2%
Operating Expenses+	8.54M	5.08M	5M	14.06M	23M	31.68M	24.54M	24.82M	21.17M	11.45M
OpEx % of Revenue	-	-	-	-	-62.84%	-	-	-	-	13.49%
Selling, General & Admin	3.59M	2.83M	4.02M	5.77M	5.8M	9.36M	9.3M	10.87M	10.69M	7.04M
SG&A % of Revenue	-	-	-	-	-15.84%	-	-	-	-	8.29%
Research & Development	4.95M	2.25M	977K	8.29M	17.2M	22.33M	15.23M	13.96M	10.48M	4.41M
R&D % of Revenue	-	-	-	-	-47.01%	-	-	-	-	5.2%
Other Operating Expenses	0	0	0	0	0	0	0	0	0	0
Operating Income+	-8.54M	-5.08M	-5M	-14.06M	-23M	-31.68M	-24.54M	-24.82M	-21.44M	-11.69M
Operating Margin %	-	-	-	-	62.84%	-	-	-	-	-13.77%
Operating Income Growth %	-0.15%	0.4%	0.02%	-1.81%	-0.64%	-0.38%	0.23%	-0.01%	0.14%	0.45%
EBITDA+	-8.45M	-5.01M	-4.91M	-13.95M	-22.84M	-31.46M	-24.28M	-24.54M	-21.17M	-11.45M
EBITDA Margin %	-	-	-	-	62.4%	-	-	-	-	-13.49%
EBITDA Growth %	-0.16%	0.41%	0.02%	-1.84%	-0.64%	-0.38%	0.23%	-0.01%	0.14%	0.46%
D&A (Non-Cash Add-back)	87K	77K	85K	110K	164K	219K	260K	285K	265K	240K
EBIT	-8.49M	-4.98M	-4.95M	-13.95M	-23.25M	-31.81M	-24.46M	-24.28M	-17.19M	-11.55M
Net Interest Income+	48K	101K	47K	0	252	-127K	82K	545K	0	-77K
Interest Income	48K	101K	47K	0	252	127	82K	545K	0	0
Interest Expense	0	0	0	0	0	0	0	0	0	77K
Other Income/Expense	48K	101K	47K	115K	-252K	-127K	82K	545K	4.25M	70K
Pretax Income+	-8.49M	-4.98M	-4.95M	-13.95M	-23.25M	-31.81M	-24.46M	-24.28M	-17.19M	11.62M
Pretax Margin %	-	-	-	-	63.53%	-	-	-	-	13.69%
Income Tax+	0	0	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-8.49M	-4.98M	-4.95M	-13.95M	-23.25M	-31.81M	-24.46M	-24.28M	-17.19M	11.62M
Net Margin %	-	-	-	-	63.53%	-	-	-	-	13.69%
Net Income Growth %	0.08%	0.41%	0.01%	-1.82%	-0.67%	-0.37%	0.23%	0.01%	0.29%	1.68%
Net Income (Continuing)	-8.49M	-4.98M	-4.95M	-13.95M	-23.25M	-31.81M	-24.46M	-24.28M	-17.19M	11.62M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-6.88	-4.00	-3.92	-10.05	-13.64	-14.09	-10.09	-9.93	-4.48	2.19
EPS Growth %	0.17%	0.42%	0.02%	-1.56%	-0.36%	-0.03%	0.28%	0.02%	0.55%	1.49%
EPS (Basic)	-6.88	-4.00	-3.92	-10.05	-13.64	-14.09	-10.09	-9.93	-4.48	2.19
Diluted Shares Outstanding	1.23M	1.25M	1.26M	1.39M	1.71M	2.26M	2.42M	2.45M	3.84M	5.31M
Basic Shares Outstanding	1.23M	1.25M	1.26M	1.39M	1.7M	2.26M	2.42M	2.45M	3.84M	5.31M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	16.79M	10.44M	9.62M	10.27M	3.36M	43.24M	23.28M	3.11M	1.9M	385K
Cash & Short-Term Investments	15.96M	9.99M	7.76M	7.06M	569K	41.94M	22.09M	2.98M	1.3M	187K
Cash Only	428K	547K	2.48M	942K	536K	37.83M	18.86M	772K	1.3M	187K
Short-Term Investments	15.53M	9.44M	5.27M	6.12M	33K	4.11M	3.24M	2.21M	0	0
Accounts Receivable	759K	306K	672K	2.01M	0	0	0	91K	51K	63K
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	27.08
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	0	2.63M	304K	86K	0	23K	135K
Total Non-Current Assets+	292K	322K	1.8M	958K	3.17M	8.02M	6M	5.34M	2.31M	1.45M
Property, Plant & Equipment	271K	297K	392K	651K	3.13M	7.96M	5.95M	5.32M	2.1M	1.24M
Fixed Asset Turnover	-	-	-	-	-0.12x	-	-	-	-	0.68x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	20	16	13	16	13K	27K	17K	9	3K	0
Long-Term Investments	0	0	0	0	0	0	0	0	185K	184K
Other Non-Current Assets	20.98K	24.98K	1.41M	306.98K	32K	26K	27K	22.99K	19K	22K
Total Assets+	17.08M	10.77M	11.42M	11.23M	6.53M	51.26M	29.28M	8.45M	4.21M	1.83M
Asset Turnover	-	-	-	-	-0.06x	-	-	-	-	0.46x
Asset Growth %	0.72%	-0.37%	0.06%	-0.02%	-0.42%	6.84%	-0.43%	-0.71%	-0.5%	-0.56%
Total Current Liabilities+	2.95M	864K	5.54M	6.21M	17.65M	11.23M	6.32M	8.8M	7.8M	8.98M
Accounts Payable	1.45M	712K	2.1M	4.55M	14.68M	5.42M	3.7M	6.22M	4.95M	6.08M
Days Payables Outstanding	6.09K	3.38K	9.02K	15.09K	14.64K	9.03K	5.19K	7.97K	6.82K	9.25K
Short-Term Debt	0	0	0	0	0	0	0	0	603K	0
Deferred Revenue (Current)	0	0	1000K	0	0	0	0	0	0	0
Other Current Liabilities	0	0	0	622K	714K	1.9M	1.07M	1.06M	2.24M	2.35M
Current Ratio	5.69x	12.09x	1.74x	1.65x	0.19x	3.85x	3.69x	0.35x	0.24x	0.04x
Quick Ratio	5.69x	12.09x	1.74x	1.65x	0.19x	3.85x	3.69x	0.35x	0.24x	0.04x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	0	0	0	1.1M	4.56M	3.62M	2.67M	1.27M	618K
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	1.1M	4.56M	3.62M	2.67M	672K	171K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	0	0	594K	447K
Total Liabilities	2.95M	864K	5.54M	6.21M	18.76M	15.79M	9.94M	11.47M	9.07M	9.6M
Total Debt+	0	0	0	0	2.37M	7.22M	5.08M	4.09M	1.27M	720K
Net Debt	-428K	-547K	-2.48M	-942K	1.83M	-30.61M	-13.78M	3.32M	-25K	533K
Debt / Equity	-	-	-	-	-	0.20x	0.26x	-	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-	-	-	-	-151.86x
Total Equity+	14.13M	9.9M	5.88M	5.02M	-12.22M	35.46M	19.34M	-3.02M	-4.86M	-7.76M
Equity Growth %	1.12%	-0.3%	-0.41%	-0.15%	-3.44%	3.9%	-0.45%	-1.16%	-0.61%	-0.6%
Book Value per Share	11.45	7.95	4.65	3.61	-7.17	15.71	7.98	-1.23	-1.27	-1.46
Total Shareholders' Equity	14.13M	9.9M	5.88M	5.02M	-12.22M	35.46M	19.34M	-3.02M	-4.86M	-7.76M
Common Stock	11K	11K	11K	11K	11K	12K	12K	12K	13K	14K
Retained Earnings	-70.14M	-75.12M	-80.08M	-94.02M	-117.28M	-149.09M	-173.54M	-197.82M	-215.01M	-226.64M
Treasury Stock	0	0	0	0	0	-116K	-116K	-116K	-116K	-116K
Accumulated OCI	0	0	0	4.41M	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-7.41M	-5.86M	-2.36M	-12.39M	-11.25M	-35.19M	-26.27M	-19.32M	-20.46M	-9.09M
Operating CF Margin %	-	-	-	-	30.73%	-	-	-	-	-10.71%
Operating CF Growth %	-0.65%	0.21%	0.6%	-4.24%	0.09%	-2.13%	0.25%	0.26%	-0.06%	0.56%
Net Income	-8.49M	-4.98M	-4.95M	-13.95M	-23.25M	-31.81M	-24.46M	-24.28M	-17.19M	-11.62M
Depreciation & Amortization	87K	77K	85K	110K	164K	219K	260K	285K	265K	240K
Stock-Based Compensation	835K	635K	554K	917K	789K	2.56M	1.37M	1.68M	1.49M	750K
Deferred Taxes	0	0	0	0	0	0	0	1.34M	0	0
Other Non-Cash Items	108K	121K	62K	102K	0	0	0	-1.34M	-4.53M	-147K
Working Capital Changes	50K	-1.71M	1.89M	431K	11.05M	-6.16M	-3.43M	2.99M	-496K	1.69M
Change in Receivables	204K	379K	-2.79M	-238K	690K	1.49M	335K	1.07M	-475K	401K
Change in Inventory	0	0	975K	0	0	0	0	0	0	0
Change in Payables	-373K	-824K	1.08M	3.12M	10.13M	-9.26M	-1.72M	2.52M	-1.27M	1.13M
Cash from Investing+	-11.28M	5.98M	3.99M	-1.22M	5.62M	-4.45M	323K	998K	2.19M	12K
Capital Expenditures	-45K	-103K	-180K	-369K	-473K	-378K	-330K	-29K	-18K	0
CapEx % of Revenue	-	-	-	-	-1.29%	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-11.24M	6.08M	4.17M	-849K	6.09M	-4.07M	653K	0	2.21M	12K
Cash from Financing+	14.87M	0	314K	12.06M	5.22M	76.94M	6.97M	238K	18.98M	7.97M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	14.87M	0	314K	12.06M	3.16M	16.32M	5K	0	0	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-7.45M	-5.96M	-2.54M	-12.76M	-11.72M	-35.57M	-26.59M	-19.35M	-20.48M	-9.09M
FCF Margin %	-	-	-	-	32.02%	-	-	-	-	-10.71%
FCF Growth %	-0.6%	0.2%	0.57%	-4.01%	0.08%	-2.04%	0.25%	0.27%	-0.06%	0.56%
FCF per Share	-6.04	-4.78	-2.01	-9.19	-6.87	-15.76	-10.97	-7.91	-5.33	-1.71
FCF Conversion (FCF/Net Income)	0.87x	1.18x	0.48x	0.89x	0.48x	1.11x	1.07x	0.80x	1.19x	-0.78x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-81.6%	-41.46%	-62.76%	-256.02%	-	-273.75%	-89.25%	-297.38%	-	-
Return on Invested Capital (ROIC)	-79.41%	-33.07%	-58.8%	-282.35%	-	-	-353.35%	-634.18%	-	-
Gross Margin	-	-	-	-	200%	-	-	-	-	100%
Net Margin	-	-	-	-	6353.28%	-	-	-	-	1369.02%
Debt / Equity	-	-	-	-	-	0.20x	0.26x	-	-	-
Interest Coverage	-	-	-	-	-	-	-	-	-	-151.86x
FCF Conversion	0.87x	1.18x	0.48x	0.89x	0.48x	1.11x	1.07x	0.80x	1.19x	-0.78x
Revenue Growth	-	-	-	-	-	100%	-	-	-	-

Frequently Asked Questions

Valuation & Price

Brainstorm Cell Therapeutics Inc. (BCLI) has a price-to-earnings (P/E) ratio of 0.3x. This may indicate the stock is undervalued or faces growth challenges.

Growth & Financials

Brainstorm Cell Therapeutics Inc. (BCLI) reported $0.8M in revenue for fiscal year 2024.

Brainstorm Cell Therapeutics Inc. (BCLI) grew revenue by 0.0% over the past year. Growth has been modest.

Brainstorm Cell Therapeutics Inc. (BCLI) reported a net loss of $11.4M for fiscal year 2024.

Dividend & Returns

Brainstorm Cell Therapeutics Inc. (BCLI) had negative free cash flow of $9.5M in fiscal year 2024, likely due to heavy capital investments.